BACKGROUND: Vaginal misoprostol has been shown to be an effective single agent for
medical abortion. This randomized, double-blinded, placebo-controlled trial compared a …

In France, mifepristone in association with orally administered misoprostol is widely used for
the early termination of pregnancy (up to 49 days' gestation). In other centers, mifepristone in …

Mifepristone medical abortion has been a valuable addition to the reproductive health
options of women. Aspects of its provision have however sometimes limited its accessibility …

Objective To compare the efficacy, adverse effects and acceptability of the three most
common misoprostol regimens used with mifepristone for medical abortion. Design …

Medical methods of early abortion differ from surgical methods in that women themselves
can potentially administer the regimens. As currently researched and offered, however, the …

Second trimester abortion is associated with higher rates of complications compared to first
trimester abortion. Dilatation and evacuation (D&E) and medical induction using misoprostol …

Abstract Background In the United States, mifepristone is available for medical abortion (for
use with misoprostol) only with Risk Evaluation and Mitigation Strategy (REMS) restrictions …

M m,~ uch attention has been focused on the potential of medical abortion to change the
character of pregnancy termination services in the United States. Because medical abortion …

Mifepristone was recently approved in the United States. Regimens with shorter intervals
may be more acceptable. The objective of this study was to determine whether the oral route …

An estimated 60 000–70 000 women die annually from complications of unsafe abortion and
hundreds of thousands more suffer long-term consequences which include chronic pelvic …